Published on
July 1, 2024
- 02:30 GMT
Broadgate Advises Boston Oncology Arabia on USD 35 Million Investment from TVM Capital
Investment Expected to Expedite Boston Oncology Arabia's Move into Full Formulation and Fill and Finish Manufacturing RIYADH , CENTRAL, KINGDOM OF SAUDI ARABIA, July 1, 2024 /EINPresswire.com/ -- Broadgate Advisers (“Broadgate”) has successfully advised Boston Oncology Arabia (the “Company” or “BOA”), a leading bio-generic drugs manufacturing company based in Saudi Arabia, on a USD35 million investment from TVM Capital Healthcare (“TVM”). From its headquarters in Riyadh and production facility in …
Distribution channels:
Banking, Finance & Investment Industry, Business & Economy
...
